<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="epub">2692-8205</issn></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS206302</article-id><article-id pub-id-type="doi">10.1101/2025.06.03.657596</article-id><article-id pub-id-type="archive">PPR1032402</article-id><article-version-alternatives><article-version article-version-type="status">preprint</article-version><article-version article-version-type="number">1</article-version></article-version-alternatives><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Heterogeneity in human brain clearance adds resilience against tauopathy – a computational model informed by glymphatic MRI</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Brennan</surname><given-names>Georgia S.</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>Travis B.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Oliveri</surname><given-names>Hadrien</given-names></name><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Vinje</surname><given-names>Vegard</given-names></name><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Ringstad</surname><given-names>Geir</given-names></name><xref ref-type="aff" rid="A5">5</xref><xref ref-type="aff" rid="A7">7</xref><xref ref-type="aff" rid="A8">8</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Eide</surname><given-names>Per Kristian</given-names></name><xref ref-type="aff" rid="A6">6</xref><xref ref-type="aff" rid="A8">8</xref><xref ref-type="aff" rid="A10">10</xref></contrib><contrib contrib-type="author"><name><surname>Goriely</surname><given-names>Alain</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rognes</surname><given-names>Marie E.</given-names></name><xref ref-type="corresp" rid="CR1">*</xref><xref ref-type="aff" rid="A9">9</xref><xref ref-type="aff" rid="A10">10</xref></contrib></contrib-group><aff id="A1"><label>1</label>Mathematical Institute, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/052gg0110</institution-id><institution>University of Oxford</institution></institution-wrap>, <city>Oxford</city>, <country country="GB">UK</country></aff><aff id="A2"><label>2</label>Department of Mathematics and Statistics, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/0405mnx93</institution-id><institution>Texas Tech University</institution></institution-wrap>, <city>Lubbock</city>, <state>TX</state>, <country country="US">USA</country></aff><aff id="A3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/044g3zk14</institution-id><institution>Max Planck Institute for Plant Breeding Research</institution></institution-wrap>, <city>Cologne</city>, <country country="DE">Germany</country></aff><aff id="A4"><label>4</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03ez40v33</institution-id><institution>BI Norwegian Business School</institution></institution-wrap>, <city>Oslo</city>, <country country="NO">Norway</country></aff><aff id="A5"><label>5</label>Department of Radiology, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j9c2840</institution-id><institution>Oslo University Hospital</institution></institution-wrap> – Rikshospitalet, <city>Oslo</city>, <country country="NO">Norway</country></aff><aff id="A6"><label>6</label>Department of Neurosurgery, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00j9c2840</institution-id><institution>Oslo University Hospital</institution></institution-wrap> – Rikshospitalet, <city>Oslo</city>, <country country="NO">Norway</country></aff><aff id="A7"><label>7</label>Department of Geriatrics and Internal Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/05yn9cj95</institution-id><institution>Sorlandet Hospital</institution></institution-wrap>, <city>Arendal</city>, <country country="NO">Norway</country></aff><aff id="A8"><label>8</label>Institute of Clinical Medicine, Faculty of Medicine, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xtthb56</institution-id><institution>University of Oslo</institution></institution-wrap>, <city>Oslo</city>, <country country="NO">Norway</country></aff><aff id="A9"><label>9</label>Department of Numerical Analysis and Scientific Computing, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/00vn06n10</institution-id><institution>Simula Research Laboratory</institution></institution-wrap>, <city>Oslo</city>, <country country="NO">Norway</country></aff><aff id="A10"><label>10</label>K. G. Jebsen Centre for Brain Fluid Research, <institution-wrap><institution-id institution-id-type="ror">https://ror.org/01xtthb56</institution-id><institution>University of Oslo</institution></institution-wrap>, <city>Oslo</city>, <country country="NO">Norway</country></aff><author-notes><corresp id="CR1">
<label>*</label><email>meg@simula.no</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>08</day><month>06</month><year>2025</year></pub-date><pub-date pub-type="preprint"><day>06</day><month>06</month><year>2025</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0 International license</ext-link>.</license-p></license></permissions><abstract><p id="P1">Neurotoxic protein fragments such as amyloid-beta and tau accumulate in characteristic staging patterns in Alzheimer’s disease (AD). The brain clears such metabolic substances via multiple different systems, including via the glymphatic (extracellular/extravascular) pathway. Here, we ask how the distinct features that characterize human glymphatic function would affect the prion-like cascade of protein invasion associated with AD. To address this question, we extract and analyze individual clearance rates from human glymphatic MRI (gMRI) data sets. These clearance rates define subject-specific maps of glymphatic clearance that vary both across cortical lobes and Braak staging regions. We apply these clearance maps as initial states in a computational network model linking misfolded proteins, tissue damage, and local clearance to simulate a series of individual proteinopathy trajectories. Our results show that the spatial heterogeneity in initial clearance induces characteristic propagation patterns, delaying and redirecting the disease progression. Moreover, reducing this spatial heterogeneity accelerates disease progression and induces staging patterns typically associated with AD. A comparison between well-rested subjects and subjects who underwent a single night of sleep deprivation did not reveal differences in initial clearance maps nor in simulated disease progression. These findings suggest that spatial heterogeneity in brain clearance may be a key factor for neurodegenerative resilience.</p></abstract></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">The brain represents just 2% of the average human’s body weight, but consumes approximately 20% of the body’s energy<sup><xref ref-type="bibr" rid="R1">1</xref></sup>. The by-products of its metabolism include protein fragments such as misfolded amyloid-β (Aβ), tau proteins (τ) and α-synuclein, which are implicated in the onset and progression of neurodegenerative diseases<sup><xref ref-type="bibr" rid="R2">2</xref></sup>. Lacking classical lymphatic vessels<sup><xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref></sup>, the brain clears such metabolic substances and other solutes via multiple systems<sup><xref ref-type="bibr" rid="R5">5</xref></sup>, including clearance across the blood-brain barrier (BBB), intracellular clearance by degradation and autophagy, and glymphatic clearance mediated by interstitial fluid (ISF) and/or cerebrospinal fluid (CSF) flow<sup><xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R7">7</xref></sup>. The exact proportions of clearance remain unknown and likely vary both between species and substances. While clearance of τ proteins is believed to rely primarily on degradation and glymphatic mechanisms, Aβ clearance is dominated by transport across the BBB5. Independently of the mechanism, BBB and glymphatic clearance are intrinsically connected in that impairment in one pathway affects the other<sup><xref ref-type="bibr" rid="R8">8</xref></sup>.</p><p id="P3">A growing body of evidence suggests that the glymphatic system in particular plays a pivotal role in maintaining healthy brain clearance<sup><xref ref-type="bibr" rid="R9">9</xref></sup>. Mice with impaired glymphatic function show diminished Aβ<sup><xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R10">10</xref></sup> and τ<sup><xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R12">12</xref></sup> clearance, with early results indicating that the same may hold also for α-synuclein<sup><xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R14">14</xref></sup>. Intrathecal contrast-enhanced glymphatic magnetic resonance imaging (gMRI), utilizing an MRI contrast agent as a CSF tracer, provides evidence of glymphatic clearance also in humans and reveals substantial inter-individual variability<sup><xref ref-type="bibr" rid="R7">7</xref>, <xref ref-type="bibr" rid="R15">15</xref>–<xref ref-type="bibr" rid="R17">17</xref></sup>. As vascular and intracranial pulsatility is inherently coupled with glymphatic function<sup><xref ref-type="bibr" rid="R18">18</xref>–<xref ref-type="bibr" rid="R20">20</xref></sup>, changes in vascular stiffness and pulsatility due to ageing, hypertension or other disease states may also affect brain clearance<sup><xref ref-type="bibr" rid="R21">21</xref></sup>. Interestingly, sleep enhances glymphatic transport<sup><xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R23">23</xref></sup>, supported by slow vasomotions<sup><xref ref-type="bibr" rid="R20">20</xref></sup>, and sleep-deprivation delays brain clearance<sup><xref ref-type="bibr" rid="R24">24</xref></sup>. Still, the downstream implications of how glymphatic clearance may modulate neurodegenerative disease have remained hard to quantify.</p><p id="P4">In previous studies, using mathematical models of Aβ and τ aggregation, propagation, and clearance dynamics across the human brain connectome, we found that enhanced clearance can delay features of Alzheimer’s disease (AD) onset and progression<sup><xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R26">26</xref></sup>. Moreover, we demonstrated that heterogeneous (regionally-varying) clearance levels can alter the progression of protein pathology and contribute to the manifestation of distinct AD subtypes<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. However, none of these models were informed by measurements of human glymphatic clearance. We therefore now ask how the distinct features that characterize human glymphatic function would affect the prion-like cascade of protein invasion associated with AD<sup><xref ref-type="bibr" rid="R28">28</xref></sup>, and neurodegenerative diseases more generally.</p><p id="P5">To address this question, we extract and analyze individual clearance rates from previously collected human gMRI data sets<sup><xref ref-type="bibr" rid="R24">24</xref></sup>. These clearance rates define subject-specific maps of glymphatic clearance that vary across cortical lobes and Braak staging regions. We apply these clearance maps as initial states in a network model linking proteinopathy, damage, and clearance to simulate AD progression in each subject. Our results show that this spatial heterogeneity in initial clearance induces characteristic protein propagation patterns, delaying and redirecting the disease progression. Moreover, reducing the spatial heterogeneity yields accelerated disease progression with classical AD staging features. These findings point at spatial heterogeneity in clearance as a key factor for neurodegenerative brain resilience.</p></sec><sec id="S2" sec-type="results"><title>Results</title><p id="P6">To study the interplay between subject-specific clearance and neurotoxic protein propagation over longer time scales, we apply our previously published predictive mathematical model<sup><xref ref-type="bibr" rid="R27">27</xref></sup> describing the coupled dynamics of a misfolded protein concentration <italic>p</italic>(<italic>t</italic>) = {<italic>p<sub>i</sub></italic>(<italic>t</italic>)}<sub><italic>i</italic></sub> and a clearance level λ(<italic>t</italic>) = {<italic>λ<sub>i</sub></italic>(<italic>t</italic>)}<sub><italic>i</italic></sub>, both evolving over time <italic>t</italic> &gt; 0 and defined relative to a brain connectome network <inline-formula><mml:math id="M1"><mml:mi mathvariant="script">G</mml:mi></mml:math></inline-formula>. The brain network consists of 83 nodes representing the Lausanne multiresolution anatomical parcellation<sup><xref ref-type="bibr" rid="R29">29</xref></sup> with connecting edges derived from the connectome data of 426 subjects of the Human Connectome Project<sup><xref ref-type="bibr" rid="R30">30</xref></sup>. Model parameters were set to represent the concentration of misfolded τ-proteins interacting with an extracellular/extravascular clearance pathway.</p><sec id="S3"><title>Subject-specific clearance maps are heterogeneous and vary across Braak regions and cortical lobes</title><p id="P7">To map from volumetric gMRI data describing contrast-induced T1 signal intensity change at multiple time points to a <italic>clearance map</italic>, we fit an exponential decay curve to the median intensity values for each region, for each region of interest (ROI) and subject (<xref ref-type="fig" rid="F1">Figure 1A–C</xref>). The decay rate constants {λ<sub>0,<italic>i</italic></sub>}<sub><italic>i</italic></sub> then define a subject-specific map of <italic>clearance rates</italic>, with units of per year, varying over the 83 brain regions. The clearance maps represent initial glymphatic clearance rates of the CSF tracer, which serves as an approximation of τ protein clearance rates mediated by CSF-ISF transport. We quantify these clearance maps for each subject in a reference cohort and a sleep-deprived cohort. As expected<sup><xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R31">31</xref></sup>, the clearance maps display substantial variation between regions and subjects (<xref ref-type="fig" rid="F1">Figure 1D</xref>). In the reference cohort, the mean clearance rate across all regions and subjects is 0.723±0.179 per year. Averaging over subjects, we find significant differences in the clearance rates between regions (repeated-measures ANOVA, F(82, 820) = 7.21, <italic>p</italic> &lt; 0.001). The minimum subject-average clearance rate is 0.388±0.245 (inferior parietal cortex, right hemisphere), while the maximum subject-average clearance rate is 1.094±0.245 (entorhinal cortex, right hemisphere), with 49.4% of clearance rates among all reference subjects below the critical value of 0.72 per year as identified in previous studies<sup><xref ref-type="bibr" rid="R25">25</xref></sup> (<xref ref-type="fig" rid="F1">Figure 1E</xref>).</p><p id="P8">To further analyze these differences, we consider the average clearance rates over Braak regions I–VI (<xref ref-type="fig" rid="F1">Figure 1F, G</xref>) and cortical lobes (<xref ref-type="fig" rid="F1">Figure 1H, I</xref>). The Braak regions are of particular interest due to their role in the staging of neurodegenerative diseases<sup><xref ref-type="bibr" rid="R32">32</xref>–<xref ref-type="bibr" rid="R34">34</xref></sup>. We observe that clearance rates are decreasing through the Braak regions (<xref ref-type="fig" rid="F1">Figure 1G</xref>) with a maximum rate in Braak I (1.075±0.272) and minimum in Braak VI (0.631±0.226). Post-hoc analysis (Tukey HSD) reveals that most pairwise Braak region clearance rates are significantly different. Specifically, in the reference subject cohort, all pairwise comparisons are different except Braak regions I and II, and V and VI at the 5% significance level, and except Braak regions I and II, II and III, III and IV, IV and V, IV and VI, and V and VI at the 1% significance level. In terms of cortical lobes, the lobe with the lowest average clearance rate is the parietal (0.554±0.188) while the highest is observed in the limbic (0.894±0.15) (<xref ref-type="fig" rid="F1">Figure 1I</xref>).</p><p id="P9">Comparing the reference and sleep-deprived cohorts, we find clearance rates that are comparable at the whole brain level, and on the scale of Braak regions and cortical lobes. Moreover, we observe the same trend through the Braak regions and lobes in the sleep-deprived cohort: clearance reduces from Braak I-VI in both cohorts. At the atlas level, there are no significant differences between clearance rates in ROIs between the sleep and sleep-deprived cohorts.</p></sec><sec id="S4"><title>Subject-specific clearance maps modulate disease progression with higher clearance delaying toxic load</title><p id="P10">We then asked how the heterogeneity in these clearance maps would affect disease progression in the sense of the spread of neurotoxic proteins across the connectome. Specifically, we impose the subject-specific clearance maps {λ<sub>0,<italic>i</italic></sub>}<sub><italic>i</italic></sub> as initial conditions for the dynamic clearance levels {<italic>λ<sub>i</sub></italic>(<italic>t</italic>)}<sub><italic>i</italic></sub>. For each subject, using a high (i.e. above critical) protein concentration in the entorhinal cortex region as an initial trigger, we simulate disease trajectories as the distribution and evolution of the misfolded protein concentration <italic>p</italic> and clearance level λ across the connectome over a time frame of up to 50 years (<xref ref-type="fig" rid="F2">Figure 2</xref>).</p><p id="P11">Overall, the protein concentrations diffuse along the connectome network, saturate rapidly in vulnerable regions with subcritical clearance, and gradually reduce the clearance level to subcritical in neighboring regions. The inverse relationship between the propagation of misfolded proteins and declining clearance levels is evident through the connectome. Moreover, the initial clearance levels, accounting for subject-specific heterogeneity in brain clearance, clearly skews the propagation of toxic proteins (<xref ref-type="fig" rid="F2">Figure 2A, B</xref>). These trends are also evident when considering the average protein concentration <inline-formula><mml:math id="M2"><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> and clearance level <inline-formula><mml:math id="M3"><mml:mover accent="true"><mml:mi>λ</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> across each brain as a model biomarker for toxic load and disease progression (<xref ref-type="fig" rid="F2">Figure 2C, D</xref>). Importantly, we further observe that the average concentrations plateau, at intermediate values of 30–75% for most subjects, rather than reach saturation (100%) within the time frame. This pattern can be seen as a consequence of the high (i.e. above critical) initial clearance values in ≈50% of regions on average across the reference cohort, which delay saturation in these regions. The high connectivity of network nodes with the highest initial clearance, specifically within Braak regions II and III, also adds resilience<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. We remark that, by model construction, all trajectories will eventually transition to a globally saturated state, but here not within a reasonable time frame.</p><p id="P12">To further study the relationship between the clearance maps and disease progression, we examine the <italic>time-to-threshold t</italic><sub>5%,<italic>i</italic></sub> and the <italic>early-time toxic load</italic>, defined as the time when the protein concentration in network region <italic>i</italic> reaches a threshold of 5% of the maximum concentration and the brain-wide average protein concentration <inline-formula><mml:math id="M4"><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> at <italic>t</italic> = 5 years, respectively. Importantly, the time-to-threshold increases dramatically for initial clearance rates surpassing the critical value (<xref ref-type="fig" rid="F2">Figure 2E</xref>). Furthermore, the early-time toxic load decreases with increasing average clearance rate (Pearson correlation coefficient <italic>r</italic> = −0.968, <xref ref-type="fig" rid="F2">Figure 2F</xref>) and increases with the percentage of network regions with initial subcritical clearance (<italic>r</italic> = 0.995, <xref ref-type="fig" rid="F2">Figure 2G</xref>).</p></sec><sec id="S5"><title>Subject-specific clearance maps define characteristic activation patterns with long plateau phases</title><p id="P13">We now turn from the global view of disease progression to examine disease trajectories in terms of the invasion patterns of the network regions, cortical lobes, and Braak regions. Both the topology of the brain connectome network and the local node dynamics, with the latter depending on the clearance levels, affect the simulated protein propagation pathways<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. Their relative importance when informed by clinical observations of human brain clearance is however not known.</p><p id="P14">To begin by studying the disease trajectory at a group level, we average the simulated misfolded protein concentrations at each time across the reference subjects, and further consider averages over cortical lobes and over Braak regions (<xref ref-type="fig" rid="F3">Figure 3</xref>). We observe a rapid and eventually near complete saturation of the basal ganglia and parietal lobe, followed by limited invasion reaching clear plateaus in the frontal, occipital, and temporal lobes, and very limited spread to the limbic region over a 5–10 year simulation time frame (<xref ref-type="fig" rid="F3">Figure 3A, B</xref>).</p><p id="P15">Interestingly, the misfolded protein propagation through the Braak regions reveals a non-standard activation pattern. In terms of the time-to-threshold <italic>t</italic><sub>10%</sub>, the average order of activation is: I, VI, IV, V, II, III (<xref ref-type="fig" rid="F3">Figure 3C</xref>). Braak region I includes the entorhinal cortex and is activated first by model construction. On the other hand, Braak regions II and III exhibit low-to-moderate concentrations throughout the simulation time frame. This pattern is contrary to the typical progression of AD<sup><xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R33">33</xref></sup>, and can be viewed in light of the characteristic differences in initial clearance rates between Braak regions, in particular the higher rates in Braak regions II and III compared to IV–VI (<xref ref-type="fig" rid="F1">Figure 1G</xref>). Indeed, examining also the individual disease trajectories, the predicted time-to-threshold in the Braak regions reveal differences in activation between Braak regions II and V, II and VI, III and V, and III and VI (<xref ref-type="fig" rid="F3">Figure 3D</xref>), with Braak regions V and VI saturating more rapidly (Welch’s <italic>t</italic>-test). This observation also aligns with the strong correlation between early toxic load and average clearance rates (<xref ref-type="fig" rid="F2">Figure 2F</xref>).</p><p id="P16">We also simulated disease trajectories for the subjects in the sleep-deprived cohort. We found no significant differences between the reference and sleep-deprived cohort in terms of progression timescales and activation order across Braak regions and lobes, as expected given the only minor differences in extracted clearance rates (<xref ref-type="supplementary-material" rid="SD1">Figure 6</xref>).</p></sec><sec id="S6"><title>Reduced heterogeneity in clearance alters Braak staging patterns and disease phases</title><p id="P17">To further investigate the role of subject-specific clearance heterogeneity, we next ask how reduced heterogeneity would affect disease trajectories. In particular, we introduce a homogeneous average clearance map <inline-formula><mml:math id="M5"><mml:msub><mml:mover accent="true"><mml:mi>λ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mn>0.7145</mml:mn></mml:math></inline-formula> defined across the connectome by averaging the initial clearance rates across all network regions and across all subjects. We then again simulate the evolution and distribution of the misfolded protein concentrations and clearance levels given an above-critical initial concentration in the entorhinal cortex, but now with this homogeneous clearance map as the initial clearance. The simulated disease trajectory is thus attributed purely to the topology of the network, with regional resilience initially stemming only from local connectivity<sup><xref ref-type="bibr" rid="R27">27</xref></sup>.</p><p id="P18">The homogenization of the initial clearance levels substantially alter the disease trajectories (<xref ref-type="fig" rid="F4">Figure 4</xref>). With homogeneous initial clearance, we no longer observe the characteristic plateaus in the average concentration curves, but rather a steady increase over a longer time window after an initial (dormant) phase (<xref ref-type="supplementary-material" rid="SD1">Figure 4A</xref>). Moreover, examining the activation patterns, we observe that the proteins spread from the temporal lobe to the frontal, parietal, and occipital lobes (<xref ref-type="fig" rid="F4">Figure 4B, C</xref>), which fundamentally differs from the disease progressions in the reference cohort (<xref ref-type="fig" rid="F3">Figure 3B–D</xref>), but reflects the Braak staging pattern associated with AD (<xref ref-type="fig" rid="F4">Figure 4D</xref>).</p><p id="P19">Overall, in 50 years of simulated tauopathy, the reference cohort reaches only about 60% of global misfolded protein saturation on average. In contrast, given homogeneous initial clearance, the average concentration initially increases more slowly but relatively quickly advances from 40% to 80%, and reaches saturation much faster than in the reference subjects. This behavior can be attributed to the presence of healthy (i.e., above a lower threshold) clearance rates for each of the subjects in the reference cohort. Indeed, on average, about 50% of the clearance rates λ<sub><italic>i</italic>,0</sub> exceed the lower critical threshold λ<sub>crit</sub> = 0.72 for each subject. The presence of higher initial clearance rates, especially in the ventral brain regions, ultimately slows down and redirects the invasion of misfolded proteins.</p></sec><sec id="S7"><title>Subject-specific heterogeneous clearance maps alter regional involvement levels</title><p id="P20">Finally, as a means of providing a more detailed description of average invasion patterns, we synthetically emulate the neuroimaging-based τ staging approach proposed by Cho <italic>et al.</italic> (2016) <sup><xref ref-type="bibr" rid="R35">35</xref></sup>. We first simulate a longitudinal course of synthetic AV1451 PET scans for each model. Next, using the simulated tauopathy level across ROIs as a proxy for the regional SUVR intensity measures, we compute Z-scores and the ROI levels of involvement for both the reference cohort and homogeneous clearance scenario (see <xref ref-type="sec" rid="S9">Methods</xref>). Comparing the twenty most involved regions between the scenarios, we find that the heterogeneous initial clearance maps alters the ordering of the involved regions and yield a more distributed level of involvement compared to a homogeneous clearance (<xref ref-type="table" rid="T1">Table 1</xref>), again indicating that the heterogeneity in clearance observed in the reference cohort adds resilience against proteinopathy.</p></sec></sec><sec id="S8" sec-type="discussion"><title>Discussion</title><p id="P21">Brain resilience is an essential modulating factor of neurodegeneration<sup><xref ref-type="bibr" rid="R36">36</xref>, <xref ref-type="bibr" rid="R37">37</xref></sup>. Even intuitively, the proper clearance of metabolic solutes from the brain defines a natural defense against abnormal accumulations of neurotoxic aggregates. The glymphatic system plays a key role in maintaining healthy brain clearance, and impaired glymphatic function is associated with reduced clearance of Aβ and τ<sup><xref ref-type="bibr" rid="R6">6</xref>, <xref ref-type="bibr" rid="R9">9</xref>–<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R38">38</xref></sup>. Yet, the time scales spanned by these processes, ranging from seconds to decades, pose a significant challenge when it comes to pinpointing the mechanisms linking brain clearance and proteinopathies. Previously, by introducing a coupled mathematical model of neurotoxic protein propagation and clearance across the human connectome, we demonstrated that a dynamic feedback loop between brain clearance and neurotoxic protein levels has the potential to alter neurodegenerative disease onset and progression<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. Here, we inform this model by consecutive, CSF-tracer enhanced MRI data<sup><xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R39">39</xref></sup>, thus bridging between human gMRI, biophysical clearance hypotheses, and proteinopathies.</p><p id="P22">By analyzing the decay of intrathecal MRI contrast-induced change in T1 signal intensity in the brain parenchyma, we identify subject-specific clearance maps that are spatially heterogeneous and vary across Braak staging regions and cortical lobes. In particular, we identify higher clearance levels in ventral areas, including in Braak regions II and III. Regional variations in clearance levels align well with previous reports of spatial heterogeneity in e.g. blood perfusion<sup><xref ref-type="bibr" rid="R40">40</xref></sup>, glial cell population<sup><xref ref-type="bibr" rid="R41">41</xref></sup> and perivascular spaces<sup><xref ref-type="bibr" rid="R42">42</xref></sup>, all factors that have been proposed to modulate the glymphatic system<sup><xref ref-type="bibr" rid="R6">6</xref></sup>. We find that these clearance maps, in spite of substantial inter-individual variation, induce characteristic protein propagation patterns with long plateau phases and atypical Braak staging, avoiding or delaying toxic protein saturation. Moreover, when reducing the spatial variation in the clearance maps by considering averaged and homogenized initial clearance, we observe accelerated disease progression and recover the classical Braak staging patterns typical of AD. These global biomarker curves are in agreement with the sigmoidal clinical biomarker models of neurodegeneration recorded by Jack <italic>et al.</italic> (2013)<sup><xref ref-type="bibr" rid="R43">43</xref></sup>.</p><p id="P23">Concurrently, studies have shown<sup><xref ref-type="bibr" rid="R44">44</xref></sup> that higher segregation of functional connections into distinct large-scale networks supports cognitive resilience in AD, and higher structural network efficiency is also associated with increased resilience to cognitive decline<sup><xref ref-type="bibr" rid="R45">45</xref></sup>. Hub-like structural brain network properties are impaired in AD, and analysis of ADNI data relates more hub-like regions to higher cognitive performance independent of Aβ burden, τ and WM lesions, indicative of increased resilience from regional connectivity<sup><xref ref-type="bibr" rid="R46">46</xref></sup>. Moreover, the small-world properties of the network are theoretically robust to random insults<sup><xref ref-type="bibr" rid="R47">47</xref></sup>, and highly connected nodes require a higher initial toxic seed to overwhelm local clearance<sup><xref ref-type="bibr" rid="R27">27</xref></sup>. Our results suggest that the spatial heterogeneity characteristic of glymphatic human brain clearance is an additional factor significantly contributing to brain resilience.</p><p id="P24">The variability in clearance maps between individuals results in variability in cascading τ trajectories. Previous studies indicate that individual predictions of cognitive decline are less satisfactory from a clinical perspective due to considerable variance<sup><xref ref-type="bibr" rid="R48">48</xref>–<xref ref-type="bibr" rid="R50">50</xref></sup>. We note that we recover considerable variations in our simulations directly from differences in the initial glymphatic clearance maps. The identification and quantification of regional clearance capacity, across all clearance pathways, as a physiological basis of resilience, could thus complement and significantly improve individual predictions of cognitive decline. The variability between individuals also holds implications for heterogeneous clearance considerations in personalized medicine, with a potential for therapeutic effects of regionally increased clearance.</p><p id="P25">The effects of sleep and sleep-deprivation on molecular enrichment and clearance of the brain remain under active debate<sup><xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R51">51</xref>, <xref ref-type="bibr" rid="R52">52</xref></sup>. Previous analyses of the current gMRI data sets have revealed impaired molecular clearance up to two–three days after one night of sleep-deprivation<sup><xref ref-type="bibr" rid="R24">24</xref>, <xref ref-type="bibr" rid="R39">39</xref></sup>. Here, we did not identify differences in the overall clearance maps between the sleep-deprived and the reference cohorts; however, this should be viewed in light of that we estimate clearance from the decay in signal intensities over a longer time period (up to 30 days). We did not identify differences in the downstream simulated disease trajectories and progression between the two cohorts. These findings, that clearance impairment during sleep deprivation does not predict progression to Alzheimer’s disease, aligns with findings from the British Whitehall study<sup><xref ref-type="bibr" rid="R53">53</xref></sup>, which tracked individuals from their fifties to seventies and reported only a minor effect of chronic sleep deprivation (less than six hours per night) on AD risk.</p><p id="P26">In terms of limitations, our estimates of the subject-specific clearance rates are clearly based on incomplete information, with noise in the baseline signal, unknown time to peak enhancement and a limited set of time points in the clearance phase<sup><xref ref-type="bibr" rid="R24">24</xref></sup>. To increase robustness, we use local averaging to compensate for degenerate estimates (eliminating e.g. negative clearance rates), and rely on previous estimates of peak tracer enrichment<sup><xref ref-type="bibr" rid="R15">15</xref>, <xref ref-type="bibr" rid="R54">54</xref></sup>. In addition, all subjects were under clinical work-up for suspected CSF disorders [24, <xref ref-type="table" rid="T1">Table 1</xref>] and thus with potentially abnormal CSF dynamics. In terms of modeling, we note that we have only accounted for the glymphatic (extracellular/extravascular) clearance pathway as taken by the contrast agent gadubutrol. Moreover, we have considered the clearance of gadubutrol as a proxy for the clearance of τ. This choice reflects the view that the extracellular-extravascular clearance pathway primarily clears τ fragments. In contrast, for modeling e.g. Aβ, clearance across the blood-brain barrier or intracellular degradation should also be considered. However, in the context of using gadobutrol as a surrogate marker for τ clearance, as their substantial difference in molecular size (0.6 kD vs. 50 kD) and other physicochemical properties may significantly influence their transport dynamics in the perivascular and extracellular spaces. While recent studies have demonstrated that molecular size affects periarterial enrichment<sup><xref ref-type="bibr" rid="R6">6</xref></sup>, earlier studies suggest size-independent diffusion in the extracellular space<sup><xref ref-type="bibr" rid="R55">55</xref>–<xref ref-type="bibr" rid="R57">57</xref></sup>, highlighting the complexity of using gadobutrol to infer τ clearance rates. Similarly, we have also not accounted nor corrected for individual differences in brain clearance downstream, e.g. beyond the CSF spaces and meningeal lymphatics. Finally, we emphasize that we do not have access to individual patient outcomes, and thus our model predictions must be interpreted accordingly.</p><p id="P27">In conclusion, this study establishes a connection between human brain clearance dynamics at a shorter time scale and τ propagation at a very long time scale. Importantly, our findings demonstrate the potential of extracellular/extravascular clearance, as measured by gMRI, to modulate the cascade of τ invasion in AD. Moreover, we identify spatial heterogeneity in clearance as a key factor in brain resilience, with the striking variability observed between subjects highlighting the need and potential for individualized diagnostic approaches.</p></sec><sec id="S9" sec-type="methods"><title>Methods</title><sec id="S10"><title>MRI acquisition and signal intensity interpretation</title><p id="P28">In reference (<italic>n</italic> = 17) and sleep-deprived (<italic>n</italic> = 7) subject groups, CSF tracer 0.5 mmol of the MRI contrast agent Gadovist(R), Bayer, Germany (gadobutrol) was injected intrathecally and MR images were collected at multiple time points: at baseline prior to injection, at 0–1.5 h post injection, 1.5–3 h, 4.5–7 h (Day 1), 24 h (Day 2), 48 h (Day 3), and after ≈30 days, as previously reported<sup><xref ref-type="bibr" rid="R24">24</xref></sup>. During the night between Day 1 and 2 (12–24h post injection), subjects in the sleep-deprived group were deprived of sleep, while the reference group slept normally. The study<sup><xref ref-type="bibr" rid="R24">24</xref></sup> was approved by the Regional Committee for Medical and Health Research Ethics (REK) of Health Region South-East, Norway (2015/96), the Institutional Review Board of Oslo University Hospital (2015/1868), the National Medicines Agency (15/04932-7), and was registered in Oslo University Hospital Research Registry (ePhorte 2015/1868). The conduct of the study was governed by ethical standards according to the Declaration of Helsinki of 1975 (and as revised in 1983). Study participants were included after written and oral informed consent.</p></sec><sec id="S11"><title>Brain connectome network</title><p id="P29">The brain’s connectome is organized as a small-world network with high clustering and short path lengths between regions of interest<sup><xref ref-type="bibr" rid="R58">58</xref>–<xref ref-type="bibr" rid="R60">60</xref></sup>. We used a multi-scale brain connectome network graph <italic>G</italic> constructed from openly available data<sup><xref ref-type="bibr" rid="R30">30</xref></sup> of 426 subjects participating in the Human Connectome project (<xref ref-type="fig" rid="F1">Figure 1B–C</xref>). The graph nodes (or vertices), labeled <italic>i</italic> = 1,…, <italic>N</italic>, represent regions of interest in the gray matter. The graph edges represent neuronal fiber tracts between nodes and are weighted by <inline-formula><mml:math id="M6"><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msubsup><mml:mi>l</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> where <italic>n<sub>ij</sub></italic> and <italic>l<sub>ij</sub></italic> are the average number and length of fibers between regions <italic>i</italic> and <italic>j</italic> respectively <sup><xref ref-type="bibr" rid="R30">30</xref></sup>. Although we map onto regions of interest (ROIs) that correspond to the 83-region scale, we use a higher resolution network for analysis. Our simulations run on a high-resolution brain network graph consisting of <italic>N</italic> = 1015 nodes and 37,477 edges. This high-resolution graph has been shown to produce more accurate results compared to a coarse-grained network with <italic>N</italic> = 83 nodes<sup><xref ref-type="bibr" rid="R61">61</xref></sup>. The nodes in both graphs are labeled according to the Desikan-Killiany FreeSurfer parcellation<sup><xref ref-type="bibr" rid="R62">62</xref>, <xref ref-type="bibr" rid="R63">63</xref></sup>, where each ROI in the 83-node network often contains multiple nodes in the higher-resolution network.</p></sec><sec id="S12"><title>Normalized signal intensities and clearance rate maps</title><p id="P30">To capture CSF tracer clearance rates from the brain parenchyma, we consider the contrast-enhanced MR images at three time points: 24 hours, 48 hours, and after 30 days (<italic>t</italic><sub>1</sub>, <italic>t</italic><sub>2</sub>, <italic>t</italic><sub>3</sub>). Subjects without sufficient data were excluded, leaving 14 subjects in the reference and 5 subjects in the sleep-deprived group. For each subject and each image stack, the voxel-wise signal intensities were mapped onto the subject’s Desikan-Killiany parcellation via the median regional intensity value. The regional intensity values were then (i) normalized with respect to a reference ROI as previously described<sup><xref ref-type="bibr" rid="R24">24</xref></sup> and (ii) divided by the region’s 4-week intensity value for that region. For each subject, we thus compute three normalized intensities, <italic>I</italic><sub>1</sub>, <italic>I</italic><sub>2</sub> and <italic>I</italic><sub>3</sub> = 1.0 at <italic>t</italic><sub>1</sub>,<italic>t</italic><sub>2</sub>, <italic>t</italic><sub>3</sub> for each of the 83 regions of the network/parcellation (<xref ref-type="fig" rid="F1">Figure 1B–C</xref>).</p><p id="P31">A kinetic theory<sup><xref ref-type="bibr" rid="R25">25</xref></sup>, applied to a non-aggregating molecular tracer with an asymptotic baseline value of unity, suggests representing tracer clearance via an exponential decay function as: <disp-formula id="FD1"><label>(1)</label><mml:math id="M7"><mml:mrow><mml:mi>I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>a</mml:mi><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mn>1.</mml:mn></mml:mrow></mml:math></disp-formula></p><p id="P32">We determined the constants <italic>a</italic>, λ<sub>0</sub> in (1) by fitting the normalized intensity data for each subject and each region (<xref ref-type="fig" rid="F1">Figure 1A</xref>), yielding subject-specific clearance maps <inline-formula><mml:math id="M8"><mml:mrow><mml:msubsup><mml:mrow><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msubsup><mml:mi>λ</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>83</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> (<xref ref-type="fig" rid="F1">Figure 1D–E</xref>). In regions where (1) did not yield an adequate fit e.g. due to lack of decay between <italic>I</italic><sub>2</sub> and <italic>I</italic><sub>3</sub>, the regional clearance rate λ<sub>0,<italic>i</italic></sub> was instead computed as an average of clearance rates in connected neighbors with diffusive weighting based on the connectome edge data. In one of the reference subjects, no decay was observed between the intensity in any region at <italic>t</italic><sub>2</sub> and <italic>t</italic><sub>3</sub> ; this subject was excluded from the subsequent analysis. The subject-specific clearance rates were averaged for each region to produce cohort average clearance maps for the reference (<xref ref-type="fig" rid="F1">Figure 1E</xref>) and sleep-deprived cohorts.</p></sec><sec id="S13"><title>Statistical analyses of the clearance rate maps</title><p id="P33">We tested the assumptions of parametric tests, specifically normality and equality of variances, to validate the use of ANOVA. To assess normality, we analysed the ANOVA model residuals using Q-Q plots. The Q-Q plot indicates that while most residuals align with the theoretical quantiles, deviations in the tails suggest the presence of these outliers. Out of 1,079 residuals, we identified 47 moderate outliers (4.36%) and 10 severe outliers (0.93%). This level of deviation is modest and typical for real-world data; however, further investigation of these outliers may help refine the model. For equality of variances, we performed Levene’s test, which indicated a significant violation of the homogeneity of variances assumption. Consequently, we employed Welch’s ANOVA, which is robust to unequal variances. Welch’s ANOVA tests indicate differences within the clearance rates of the reference cohort (<italic>F</italic> = 77.2, <italic>p</italic> &lt; 10<sup>−3</sup>) and the sleep-deprived cohort (<italic>F</italic> = 88.1, <italic>p</italic> &lt; 10<sup>−3</sup>), indicating substantial variability within each cohort.</p><p id="P34">In the subject clearance maps, extreme outliers, defined as being outside the interval [Q<sub>1</sub> – 3IQR, Q<sub>3</sub> + 3IQR], were present in two cortical regions of one subject in the sleep-deprived cohort. Further, multiple comparisons of means (Tukey HSD tests) for each cohort revealed that this subject in the sleep-deprived cohort and two subjects in the reference cohort differed significantly from all other subjects in the respective cohorts (<xref ref-type="fig" rid="F1">Figure 1D</xref>). These three subjects were thus excluded from the subsequent analysis, leaving <italic>n</italic> = 11 in the reference group, <italic>n</italic> = 4 in the sleep-deprived group. Overall, in the remaining subjects, 7.63% of the regional clearance values were obtained as an average of neighboring regions, with an average of 6 (out of 83) regions averaged per subject with the number of averaged regions ranging from 0 for three subjects to 24 for one subject in the reference cohort.</p><p id="P35">A linear mixed model analysis reveals that the parahippocampal and entorhinal cortex, temporal pole and Hippocampus are among the most significantly different clearance rates to the rest of the regions across subjects. Further, ANOVA testing reveals that among subjects, those represented by IDs 178, 190, 191, 205, 215, 218, and 228 show significant reductions in clearance compared to the reference, as indicated by confidence intervals that exclude zero. The effect size of 0.1948, measured by partial eta squared, suggests a substantial impact of subject group on clearance value, with about 19.5% of the variance explained by group differences.</p></sec><sec id="S14"><title>Toxic protein, damage and clearance dynamics</title><p id="P36">We consider a coupled network neurodegeneration model<sup><xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R27">27</xref></sup> for the propagation and evolution of a misfolded protein concentration <italic>p<sub><italic>i</italic></sub></italic> and a regional clearance rate λ<sub><italic>i</italic></sub> (in units of per year), for each vertex <italic>i</italic>. These variables are coupled such that higher clearance rates reduce the protein concentrations while the presence of misfolded proteins degrade the clearance efficacy. Specifically, for <italic>i</italic> = 1,…, <italic>N</italic>, we compute <italic>p<sub>i</sub></italic> and <italic>λ<sub>i</sub></italic> satisfying <disp-formula id="FD2"><label>(2a)</label><mml:math id="M9"><mml:mrow><mml:mfrac><mml:mrow><mml:mtext>d</mml:mtext><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo> </mml:mo><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>ρ</mml:mi><mml:mstyle displaystyle="true"><mml:munderover><mml:mi>∑</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mtext>crit</mml:mtext></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:msubsup><mml:mi>p</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>
<disp-formula id="FD3"><label>(2b)</label><mml:math id="M10"><mml:mrow><mml:mfrac><mml:mrow><mml:mo> </mml:mo><mml:mtext>d</mml:mtext><mml:msub><mml:mi>λ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo> </mml:mo><mml:mtext>d</mml:mtext><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>i</mml:mi><mml:mi>∞</mml:mi></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula></p><p id="P37">with <italic>ρ</italic> = 0.01 the diffusion coefficient and <italic>α</italic> = 2.1 the saturation coefficient. The graph Laplacian matrix <bold>L</bold> = {<italic>L<sub>ij</sub></italic>} is used to model diffusion along axonal pathways on the network and is given by <italic>L<sub>ij</sub></italic> = (<italic>D<sub>ii</sub></italic> - <italic>A<sub>ij</sub></italic>)/<italic>v<sub>i</sub></italic> where <italic>D<sub>ii</sub></italic> and <italic>A<sub>ij</sub></italic> are the degree and weighted adjacency matrix, respectively<sup><xref ref-type="bibr" rid="R64">64</xref>, <xref ref-type="bibr" rid="R65">65</xref></sup>. The entries of the weighted adjacency matrix are <inline-formula><mml:math id="M11"><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msubsup><mml:mi>l</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> where <italic>n<sub>ij</sub></italic> is the fiber number and <italic>l<sub>ij</sub></italic> is the mean fiber length between nodes <italic>i</italic> and <italic>j</italic><sup><xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R60">60</xref>, <xref ref-type="bibr" rid="R65">65</xref></sup>. The diagonal degree matrix with <inline-formula><mml:math id="M12"><mml:msub><mml:mi>D</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:msubsup><mml:mi>∑</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>N</mml:mi></mml:msubsup><mml:mrow><mml:msub><mml:mi>A</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:math></inline-formula> expresses the connectivity of the graph. The voxel-weighting of each ROI <italic>v<sub>i</sub></italic> = <italic>V<sub>i</sub></italic>/<italic>V</italic><sub>max</sub>, where <italic>V<sub>i</sub></italic> are the number of voxels in each ROI and <italic>V</italic><sub>max</sub> = max(<italic>V<sub>i</sub></italic>), accounts for the respective sizes of each ROI in the model.</p><p id="P38">The second equation models the interplay between toxic proteins and clearance rates. Specifically, (2b) codifies a reduction in brain clearance in the presence of toxic proteins<sup><xref ref-type="bibr" rid="R66">66</xref>–<xref ref-type="bibr" rid="R68">68</xref></sup> with <italic>β</italic> = 1 quantifying the rate of degradation, while <inline-formula><mml:math id="M13"><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>i</mml:mi><mml:mi>∞</mml:mi></mml:msubsup></mml:math></inline-formula> reflects the basal clearance rate sustained within a region, even in the presence of maximal neurotoxic effects. Moreover, λ<sub>crit</sub> = 0.72 is a protein-specific critical clearance rate<sup><xref ref-type="bibr" rid="R25">25</xref></sup> above which protein aggregates do not accumulate.</p><p id="P39">To close the system, we impose the following initial conditions and constraints: <disp-formula id="FD4"><label>(3)</label><mml:math id="M14"><mml:mrow><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mtext> </mml:mtext><mml:mn>0</mml:mn><mml:mo>≤</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mi>i</mml:mi><mml:mi>∞</mml:mi></mml:msubsup><mml:mo>≤</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p id="P40">The epicenter of a misfolded protein population is modeled via a non-zero initial condition <italic>p<sub>i</sub></italic>(0) of toxic protein concentration.</p></sec><sec id="S15"><title>Quantities of interest</title><p id="P41">We analyze the progression of tauopathy using several key quantities of interest. The <italic>time-to-threshold</italic> measures how long it takes for the misfolded protein concentration in a region to exceed a predefined threshold, characterizing the rate of disease spread. The <italic>early-time toxic load</italic> quantifies the accumulated misfolded protein concentration within an initial phase of the simulation, offering insights into early disease dynamics and the efficiency of clearance mechanisms. Additionally, <italic>biomarker curves</italic> track the concentration of misfolded proteins over time, either within specific regions or as brain-wide averages. These curves help identify patterns such as plateaus or rapid progression phases. Together, these quantities provide a comprehensive framework for comparing tauopathy progression across different clearance models and assessing the impact of clearance heterogeneity.</p></sec><sec id="S16"><title>Computation of simulated PET scans and Z-scores</title><p id="P42">To synthetically emulate a longitudinal course of AV1451 PET scans, we apply the following procedure. For each subject-specific simulated disease trajectory, we extract 20 time points randomly from the average invasion window of the cohort, in total generating 220 synthetic scans from the reference cohort. For each of these scans, we compute Z-scores for the level of τ in each region and label a region as <italic>involved</italic> if <italic>Z</italic> &gt; <italic>N</italic> where <italic>N</italic> is chosen such that 70% of the data has <italic>Z</italic> ≤ <italic>N</italic>. Regions are then ordered according to their level of involvement across all simulated scans. For the homogeneous initial clearance simulation, we instead extract the protein concentrations at 220 random time points from the corresponding invasion window.</p></sec><sec id="S17"><title>Numerical solution algorithms and software</title><p id="P43">The models were solved using the software package PrYon, implemented in C++ with the SUNDIALS (SUite of Nonlinear and DIfferential/ALgebraic Equation Solvers) numerical library, specifically utilizing the CVODE solver for ordinary differential equations, and integrated into Python using a wrapper.</p></sec></sec><sec sec-type="supplementary-material" id="SM"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>Supporting Information</label><media xlink:href="EMS206302-supplement-Supporting_Information.pdf" mimetype="application" mime-subtype="pdf" id="d71aAcEbB" position="anchor"/></supplementary-material></sec></body><back><ack id="S18"><title>Acknowledgments</title><p>This publication is based on work supported by the EPSRC Centre For Doctoral Training in Industrially Focused Mathematical Modelling (EP/L015803/1) in collaboration with Simula Research Laboratory. M.E. Rognes has received funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programme under grant agreement 714892 (Waterscales), from the Research Council of Norway via FRIPRO grant #324239 (EMIx), and from the K.G. Jebsen Centre for Brain Fluid Research. The work of G.S. Brennan was supported by the EPSRC InFoMM grant EP/L015803/1. The work of T.B. Thompson was partially supported by EP/R020205/1 to A. Goriely and partially supported by the National Science Foundation under grant NSF 2325276 to T.B. Thompson.</p></ack><sec id="S19" sec-type="data-availability"><title>Data and code availability</title><p id="P44">Simulation data and code are available upon reasonable request to the corresponding author(s).</p></sec><fn-group><title>Declarations</title><fn id="FN1" fn-type="conflict"><p id="P45"><bold>Competing interests</bold></p><p id="P46">We declare no competing interests.</p></fn><fn id="FN2" fn-type="con"><p id="P47"><bold>Author contributions</bold></p><p id="P48">The authors confirm contribution to the paper as follows: study conception and design: GSB, TBT, HO, VV, GR, PKE, AG, MER; MRI data collection and analysis: GR, PKE; simulation pipeline: GSB, TBT; analysis and interpretation of results: GSB, TBT, HO, VV, GR, PKE, AG, MER; draft manuscript preparation: GSB, TBT, HO, MER. All authors reviewed the results, edited and approved the final version of the manuscript.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raichle</surname><given-names>ME</given-names></name><name><surname>Gusnard</surname><given-names>DA</given-names></name></person-group><article-title>Appraising the brain’s energy budget</article-title><source>Proc Natl Acad Sci</source><year>2002</year><volume>99</volume><fpage>10237</fpage><lpage>10239</lpage><pub-id pub-id-type="pmcid">PMC124895</pub-id><pub-id pub-id-type="pmid">12149485</pub-id><pub-id pub-id-type="doi">10.1073/pnas.172399499</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Trojanowski</surname><given-names>JQ</given-names></name><name><surname>Lee</surname><given-names>VM-Y</given-names></name></person-group><article-title>Protein transmission in neurodegenerative disease</article-title><source>Nat Rev Neurol</source><year>2020</year><volume>16</volume><fpage>199</fpage><lpage>212</lpage><pub-id pub-id-type="pmcid">PMC9242841</pub-id><pub-id pub-id-type="pmid">32203399</pub-id><pub-id pub-id-type="doi">10.1038/s41582-020-0333-7</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aspelund</surname><given-names>A</given-names></name><etal/></person-group><article-title>A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules</article-title><source>J Exp Medicine</source><year>2015</year><volume>212</volume><fpage>991</fpage><lpage>999</lpage><pub-id pub-id-type="pmcid">PMC4493418</pub-id><pub-id pub-id-type="pmid">26077718</pub-id><pub-id pub-id-type="doi">10.1084/jem.20142290</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Louveau</surname><given-names>A</given-names></name><etal/></person-group><article-title>Structural and functional features of central nervous system lymphatic vessels</article-title><source>Nature</source><year>2015</year><volume>523</volume><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="pmcid">PMC4506234</pub-id><pub-id pub-id-type="pmid">26030524</pub-id><pub-id pub-id-type="doi">10.1038/nature14432</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tarasoff-Conway</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Clearance systems in the brain - implications for Alzheimer disease</article-title><source>Nat Rev Neurol</source><year>2015</year><volume>11</volume><fpage>457</fpage><lpage>470</lpage><pub-id pub-id-type="pmcid">PMC4694579</pub-id><pub-id pub-id-type="pmid">26195256</pub-id><pub-id pub-id-type="doi">10.1038/nrneurol.2015.119</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliff</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β</article-title><source>Sci Transl Medicine</source><year>2012</year><volume>4</volume><elocation-id>147ra111</elocation-id><pub-id pub-id-type="pmcid">PMC3551275</pub-id><pub-id pub-id-type="pmid">22896675</pub-id><pub-id pub-id-type="doi">10.1126/scitranslmed.3003748</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ringstad</surname><given-names>G</given-names></name><name><surname>Vatnehol</surname><given-names>SAS</given-names></name><name><surname>Eide</surname><given-names>PK</given-names></name></person-group><article-title>Glymphatic MRI in idiopathic normal pressure hydrocephalus</article-title><source>Brain</source><year>2017</year><volume>140</volume><fpage>2691</fpage><lpage>2705</lpage><pub-id pub-id-type="pmcid">PMC5841149</pub-id><pub-id pub-id-type="pmid">28969373</pub-id><pub-id pub-id-type="doi">10.1093/brain/awx191</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Verheggen</surname><given-names>I</given-names></name><name><surname>Van Boxtel</surname><given-names>M</given-names></name><name><surname>Verhey</surname><given-names>F</given-names></name><name><surname>Jansen</surname><given-names>J</given-names></name><name><surname>Backes</surname><given-names>W</given-names></name></person-group><article-title>Interaction between blood-brain barrier and glymphatic system in solute clearance</article-title><source>Neurosci &amp; Biobehav Rev</source><year>2018</year><volume>90</volume><fpage>26</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">29608988</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bohr</surname><given-names>T</given-names></name><etal/></person-group><article-title>The glymphatic system: Current understanding and modeling</article-title><source>IScience</source><year>2022</year><volume>25</volume><pub-id pub-id-type="pmcid">PMC9460186</pub-id><pub-id pub-id-type="pmid">36093063</pub-id><pub-id pub-id-type="doi">10.1016/j.isci.2022.104987</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Deletion of aquaporin-4 in APP/PS1 mice exacerbates brain Aβ accumulation and memory deficits</article-title><source>Mol Neurodegener</source><year>2015</year><volume>10</volume><pub-id pub-id-type="pmcid">PMC4631089</pub-id><pub-id pub-id-type="pmid">26526066</pub-id><pub-id pub-id-type="doi">10.1186/s13024-015-0056-1</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliff</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury</article-title><source>J Neurosci</source><year>2014</year><volume>34</volume><fpage>16180</fpage><lpage>16193</lpage><pub-id pub-id-type="pmcid">PMC4252540</pub-id><pub-id pub-id-type="pmid">25471560</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.3020-14.2014</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harrison</surname><given-names>IF</given-names></name><etal/></person-group><article-title>Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model</article-title><source>Brain</source><year>2020</year><volume>143</volume><fpage>2576</fpage><lpage>2593</lpage><pub-id pub-id-type="pmcid">PMC7447521</pub-id><pub-id pub-id-type="pmid">32705145</pub-id><pub-id pub-id-type="doi">10.1093/brain/awaa179</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name><etal/></person-group><article-title>Decreased AQP4 Expression Aggravates α-Synuclein Pathology in Parkinson’s Disease Mice, Possibly via Impaired Glymphatic Clearance</article-title><source>J Mol Neurosci</source><year>2021</year><volume>71</volume><fpage>2500</fpage><lpage>2513</lpage><pub-id pub-id-type="pmid">33772424</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Si</surname><given-names>X</given-names></name><etal/></person-group><article-title>Neuroimaging evidence of glymphatic system dysfunction in possible REM sleep behavior disorder and Parkinson’s disease</article-title><source>npj Park Dis</source><year>2022</year><volume>8</volume><pub-id pub-id-type="pmcid">PMC9055043</pub-id><pub-id pub-id-type="pmid">35487930</pub-id><pub-id pub-id-type="doi">10.1038/s41531-022-00316-9</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ringstad</surname><given-names>G</given-names></name><etal/></person-group><article-title>Brain-wide glymphatic enhancement and clearance in humans assessed with MRI</article-title><source>JCI insight</source><year>2018</year><volume>3</volume><elocation-id>e121537</elocation-id><pub-id pub-id-type="pmcid">PMC6124518</pub-id><pub-id pub-id-type="pmid">29997300</pub-id><pub-id pub-id-type="doi">10.1172/jci.insight.121537</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eide</surname><given-names>P-K</given-names></name><name><surname>Vatnehol</surname><given-names>S</given-names></name><name><surname>Emblem</surname><given-names>K</given-names></name><name><surname>Ringstad</surname><given-names>G</given-names></name></person-group><article-title>Magnetic resonance imaging provides evidence of glymphatic drainage from human brain to cervical lymph nodes</article-title><source>Sci Reports</source><year>2018</year><volume>8</volume><elocation-id>7194</elocation-id><pub-id pub-id-type="pmcid">PMC5940793</pub-id><pub-id pub-id-type="pmid">29740121</pub-id><pub-id pub-id-type="doi">10.1038/s41598-018-25666-4</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eide</surname><given-names>PK</given-names></name><name><surname>Ringstad</surname><given-names>G</given-names></name></person-group><article-title>In vivo imaging of molecular clearance from human entorhinal cortex: a possible method for preclinical testing of dementia</article-title><source>Gerontol Geriatr Medicine</source><year>2019</year><volume>5</volume><fpage>1</fpage><lpage>49</lpage><pub-id pub-id-type="pmcid">PMC6883359</pub-id><pub-id pub-id-type="pmid">31819895</pub-id><pub-id pub-id-type="doi">10.1177/2333721419889739</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliff</surname><given-names>J</given-names></name><etal/></person-group><article-title>Cerebral arterial pulsation drives paravascular CSF-interstitial fluid exchange in the murine brain</article-title><source>J Neurosci</source><year>2013</year><volume>33</volume><fpage>18190</fpage><lpage>18199</lpage><pub-id pub-id-type="pmcid">PMC3866416</pub-id><pub-id pub-id-type="pmid">24227727</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1592-13.2013</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mestre</surname><given-names>H</given-names></name><etal/></person-group><article-title>Flow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension</article-title><source>Nat communications</source><year>2018</year><volume>9</volume><elocation-id>4878</elocation-id><pub-id pub-id-type="pmcid">PMC6242982</pub-id><pub-id pub-id-type="pmid">30451853</pub-id><pub-id pub-id-type="doi">10.1038/s41467-018-07318-3</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Veluw</surname><given-names>SJ</given-names></name><etal/></person-group><article-title>Vasomotion as a driving force for paravascular clearance in the awake mouse brain</article-title><source>Neuron</source><year>2020</year><volume>105</volume><fpage>549</fpage><lpage>561</lpage><pub-id pub-id-type="pmcid">PMC7028316</pub-id><pub-id pub-id-type="pmid">31810839</pub-id><pub-id pub-id-type="doi">10.1016/j.neuron.2019.10.033</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mortensen</surname><given-names>KN</given-names></name><etal/></person-group><article-title>Impaired glymphatic transport in spontaneously hypertensive rats</article-title><source>J Neurosci</source><year>2019</year><volume>39</volume><fpage>6365</fpage><lpage>6377</lpage><pub-id pub-id-type="pmcid">PMC6687896</pub-id><pub-id pub-id-type="pmid">31209176</pub-id><pub-id pub-id-type="doi">10.1523/JNEUROSCI.1974-18.2019</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xie</surname><given-names>L</given-names></name><etal/></person-group><article-title>Sleep drives metabolite clearance from the adult brain</article-title><source>Science</source><year>2013</year><volume>342</volume><fpage>373</fpage><lpage>377</lpage><pub-id pub-id-type="pmcid">PMC3880190</pub-id><pub-id pub-id-type="pmid">24136970</pub-id><pub-id pub-id-type="doi">10.1126/science.1241224</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang-Xie</surname><given-names>L-F</given-names></name><etal/></person-group><article-title>Neuronal dynamics direct cerebrospinal fluid perfusion and brain clearance</article-title><source>Nature</source><year>2024</year><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmcid">PMC12054998</pub-id><pub-id pub-id-type="pmid">38418877</pub-id><pub-id pub-id-type="doi">10.1038/s41586-024-07108-6</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eide</surname><given-names>PK</given-names></name><name><surname>Vinje</surname><given-names>V</given-names></name><name><surname>Pripp</surname><given-names>AH</given-names></name><name><surname>Mardal</surname><given-names>K-A</given-names></name><name><surname>Ringstad</surname><given-names>G</given-names></name></person-group><article-title>Sleep deprivation impairs molecular clearance from the human brain</article-title><source>Brain</source><year>2021</year><volume>144</volume><fpage>863</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">33829232</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>TB</given-names></name><name><surname>Meisl</surname><given-names>G</given-names></name><name><surname>Knowles</surname><given-names>TPJ</given-names></name><name><surname>Goriely</surname><given-names>A</given-names></name></person-group><article-title>The role of clearance mechanisms in the kinetics of pathological protein aggregation involved in neurodegenerative diseases</article-title><source>J Chem Phys</source><year>2021</year><volume>154</volume><elocation-id>125101</elocation-id><pub-id pub-id-type="pmid">33810689</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>GS</given-names></name><name><surname>Goriely</surname><given-names>A</given-names></name></person-group><article-title>A network aggregation model for amyloid-β dynamics and treatment of alzheimer’s diseases at the brain scale</article-title><source>J Math Biol</source><year>2025</year><volume>90</volume><fpage>1</fpage><lpage>36</lpage><pub-id pub-id-type="pmcid">PMC11787187</pub-id><pub-id pub-id-type="pmid">39891738</pub-id><pub-id pub-id-type="doi">10.1007/s00285-024-02179-5</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brennan</surname><given-names>GS</given-names></name><name><surname>Thompson</surname><given-names>TB</given-names></name><name><surname>Oliveri</surname><given-names>H</given-names></name><name><surname>Rognes</surname><given-names>ME</given-names></name><name><surname>Goriely</surname><given-names>A</given-names></name></person-group><article-title>The role of clearance in neurodegenerative diseases</article-title><source>SIAM J on Appl Math</source><year>2023</year><fpage>S172</fpage><lpage>S198</lpage><pub-id pub-id-type="doi">10.1137/22M1487801</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jucker</surname><given-names>M</given-names></name><name><surname>Walker</surname><given-names>LC</given-names></name></person-group><article-title>Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders</article-title><source>Annals Neurol</source><year>2011</year><volume>70</volume><fpage>532</fpage><lpage>540</lpage><pub-id pub-id-type="pmcid">PMC3203752</pub-id><pub-id pub-id-type="pmid">22028219</pub-id><pub-id pub-id-type="doi">10.1002/ana.22615</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daducci</surname><given-names>A</given-names></name><name><surname>Gerhard</surname><given-names>S</given-names></name><name><surname>Thiran</surname><given-names>J-P</given-names></name><etal/></person-group><article-title>The Connectome Mapper: An Open-Source Processing Pipeline to Map Connectomes with MRI</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><elocation-id>e48121</elocation-id><pub-id pub-id-type="pmcid">PMC3525592</pub-id><pub-id pub-id-type="pmid">23272041</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0048121</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kerepesi</surname><given-names>C</given-names></name><name><surname>Szalkai</surname><given-names>B</given-names></name><name><surname>Varga</surname><given-names>B</given-names></name><name><surname>Grolmusz</surname><given-names>V</given-names></name></person-group><article-title>The braingraph.org Database of High Resolution Structural Connectomes and the Brain Graph Tools</article-title><source>Cogn Neurodynamics</source><year>2017</year><volume>11</volume><fpage>483</fpage><lpage>486</lpage><pub-id pub-id-type="pmcid">PMC5637719</pub-id><pub-id pub-id-type="pmid">29067135</pub-id><pub-id pub-id-type="doi">10.1007/s11571-017-9445-1</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hovd</surname><given-names>MH</given-names></name><etal/></person-group><article-title>Population pharmacokinetic modeling of CSF to blood clearance: prospective tracer study of 161 patients under work-up for CSF disorders</article-title><source>Fluids Barriers CNS</source><year>2022</year><volume>19</volume><fpage>55</fpage><pub-id pub-id-type="pmcid">PMC9250213</pub-id><pub-id pub-id-type="pmid">35778719</pub-id><pub-id pub-id-type="doi">10.1186/s12987-022-00352-w</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Braak</surname><given-names>E</given-names></name></person-group><article-title>Neuropathological stageing of Alzheimer-related changes</article-title><source>Acta Neuropathol</source><year>1991</year><volume>82</volume><fpage>239</fpage><lpage>259</lpage><pub-id pub-id-type="pmid">1759558</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><name><surname>Alafuzoff</surname><given-names>I</given-names></name><name><surname>Arzberger</surname><given-names>T</given-names></name><name><surname>Kretzschmar</surname><given-names>H</given-names></name><name><surname>Del Tredici</surname><given-names>K</given-names></name></person-group><article-title>Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry</article-title><source>Acta Neuropathol</source><year>2006</year><volume>112</volume><fpage>389</fpage><lpage>404</lpage><pub-id pub-id-type="pmcid">PMC3906709</pub-id><pub-id pub-id-type="pmid">16906426</pub-id><pub-id pub-id-type="doi">10.1007/s00401-006-0127-z</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braak</surname><given-names>H</given-names></name><etal/></person-group><article-title>Staging of brain pathology related to sporadic Parkinson’s disease</article-title><source>Neurobiol Aging</source><year>2003</year><volume>24</volume><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">12498954</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cho</surname><given-names>H</given-names></name><etal/></person-group><article-title>In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum</article-title><source>Annals Neurol</source><year>2016</year><volume>80</volume><fpage>247</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">27323247</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nedergaard</surname><given-names>M</given-names></name><name><surname>Goldman</surname><given-names>SA</given-names></name></person-group><article-title>Glymphatic failure as a final common pathway to dementia</article-title><source>Science</source><year>2020</year><volume>370</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="pmcid">PMC8186542</pub-id><pub-id pub-id-type="pmid">33004510</pub-id><pub-id pub-id-type="doi">10.1126/science.abb8739</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Casaletto</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Brain aging rejuvenation factors in adults with genetic and sporadic neurodegenerative disease</article-title><source>Brain communications</source><year>2025</year><volume>7</volume><elocation-id>fcae432</elocation-id><pub-id pub-id-type="pmcid">PMC11734525</pub-id><pub-id pub-id-type="pmid">39816189</pub-id><pub-id pub-id-type="doi">10.1093/braincomms/fcae432</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Iliff</surname><given-names>JJ</given-names></name><etal/></person-group><article-title>The glymphatic system clears amyloid beta and tau from brain to plasma in humans</article-title><source>medRxiv</source><year>2024</year><fpage>2024</fpage><lpage>07</lpage><pub-id pub-id-type="doi">10.1101/2024.07.30.24311248</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinje</surname><given-names>V</given-names></name><etal/></person-group><article-title>Human brain solute transport quantified by glymphatic MRI-informed biophysics during sleep and sleep deprivation</article-title><source>bioRxiv</source><year>2023</year><fpage>2023</fpage><lpage>01</lpage><pub-id pub-id-type="pmcid">PMC10439559</pub-id><pub-id pub-id-type="pmid">37596635</pub-id><pub-id pub-id-type="doi">10.1186/s12987-023-00459-8</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogure</surname><given-names>D</given-names></name><etal/></person-group><article-title>Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT</article-title><source>J nuclear medicine</source><year>2000</year><volume>41</volume><fpage>1155</fpage><lpage>1162</lpage><pub-id pub-id-type="pmid">10914904</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alibhai</surname><given-names>J</given-names></name><name><surname>Diack</surname><given-names>A</given-names></name><name><surname>Manson</surname><given-names>J</given-names></name></person-group><article-title>Unravelling the glial response in the pathogenesis of Alzheimer’s Disease</article-title><source>The FASEB J</source><year>2018</year><volume>32</volume><fpage>5766</fpage><lpage>5777</lpage><pub-id pub-id-type="pmid">30376380</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sepehrband</surname><given-names>F</given-names></name><etal/></person-group><article-title>Volumetric distribution of perivascular space in relation to mild cognitive impairment</article-title><source>Neurobiol aging</source><year>2021</year><volume>99</volume><fpage>28</fpage><lpage>43</lpage><pub-id pub-id-type="pmcid">PMC7902350</pub-id><pub-id pub-id-type="pmid">33422892</pub-id><pub-id pub-id-type="doi">10.1016/j.neurobiolaging.2020.12.010</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack Jr</surname><given-names>CR</given-names></name><name><surname>Holtzman</surname><given-names>DM</given-names></name></person-group><article-title>Biomarker modeling of Alzheimer’s disease</article-title><source>Neuron</source><year>2013</year><volume>80</volume><fpage>1347</fpage><lpage>1358</lpage><pub-id pub-id-type="pmcid">PMC3928967</pub-id><pub-id pub-id-type="pmid">24360540</pub-id><pub-id pub-id-type="doi">10.1016/j.neuron.2013.12.003</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewers</surname><given-names>M</given-names></name><etal/></person-group><article-title>Segregation of functional networks is associated with cognitive resilience in Alzheimer’s disease</article-title><source>Brain</source><year>2021</year><volume>144</volume><fpage>2176</fpage><lpage>2185</lpage><pub-id pub-id-type="pmcid">PMC8370409</pub-id><pub-id pub-id-type="pmid">33725114</pub-id><pub-id pub-id-type="doi">10.1093/brain/awab112</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>FU</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Tüscher</surname><given-names>O</given-names></name><name><surname>Fellgiebel</surname><given-names>A</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><article-title>Structural network efficiency predicts resilience to cognitive decline in elderly at risk for Alzheimer’s disease</article-title><source>Front Aging Neurosci</source><year>2021</year><volume>13</volume><elocation-id>637002</elocation-id><pub-id pub-id-type="pmcid">PMC7937862</pub-id><pub-id pub-id-type="pmid">33692682</pub-id><pub-id pub-id-type="doi">10.3389/fnagi.2021.637002</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>FU</given-names></name><name><surname>Wolf</surname><given-names>D</given-names></name><name><surname>Fellgiebel</surname><given-names>A</given-names></name><collab>Alzheimer’s Disease Neuroimaging Initiative</collab></person-group><article-title>Connectivity and morphology of hubs of the cerebral structural connectome are associated with brain resilience in ad-and age-related pathology</article-title><source>Brain Imaging Behav</source><year>2019</year><volume>13</volume><fpage>1650</fpage><lpage>1664</lpage><pub-id pub-id-type="pmid">30980275</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albert</surname><given-names>R</given-names></name><name><surname>Jeong</surname><given-names>H</given-names></name><name><surname>Barabási</surname><given-names>A-L</given-names></name></person-group><article-title>Error and attack tolerance of complex networks</article-title><source>Nature</source><year>2000</year><volume>406</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">10935628</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>SJB</given-names></name><etal/></person-group><article-title>Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study</article-title><source>The Lancet Neurol</source><year>2013</year><volume>12</volume><fpage>957</fpage><lpage>965</lpage><pub-id pub-id-type="pmcid">PMC3904678</pub-id><pub-id pub-id-type="pmid">24012374</pub-id><pub-id pub-id-type="doi">10.1016/S1474-4422(13)70194-7</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jack</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Transition rates between amyloid and neurodegeneration biomarker states and to dementia: a population-based, longitudinal cohort study</article-title><source>The Lancet Neurol</source><year>2016</year><volume>15</volume><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="pmcid">PMC4784263</pub-id><pub-id pub-id-type="pmid">26597325</pub-id><pub-id pub-id-type="doi">10.1016/S1474-4422(15)00323-3</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donohue</surname><given-names>MC</given-names></name><etal/></person-group><article-title>Association between elevated brain amyloid and subsequent cognitive decline among cognitively normal persons</article-title><source>JAMA</source><year>2017</year><volume>317</volume><fpage>2305</fpage><lpage>2316</lpage><pub-id pub-id-type="pmcid">PMC5736301</pub-id><pub-id pub-id-type="pmid">28609533</pub-id><pub-id pub-id-type="doi">10.1001/jama.2017.6669</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>Q</given-names></name><etal/></person-group><article-title>Rapid lymphatic efflux limits cerebrospinal fluid flow to the brain</article-title><source>Acta neuropathologica</source><year>2019</year><volume>137</volume><fpage>151</fpage><lpage>165</lpage><pub-id pub-id-type="pmcid">PMC6338719</pub-id><pub-id pub-id-type="pmid">30306266</pub-id><pub-id pub-id-type="doi">10.1007/s00401-018-1916-x</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miao</surname><given-names>A</given-names></name><etal/></person-group><article-title>Brain clearance is reduced during sleep and anesthesia</article-title><source>Nat Neurosci</source><year>2024</year><fpage>1</fpage><lpage>5</lpage><pub-id pub-id-type="pmcid">PMC11156584</pub-id><pub-id pub-id-type="pmid">38741022</pub-id><pub-id pub-id-type="doi">10.1038/s41593-024-01638-y</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabia</surname><given-names>S</given-names></name><name><surname>Fayosse</surname><given-names>A</given-names></name><name><surname>Dumurgier</surname><given-names>J</given-names></name><name><surname>Singh-Manoux</surname><given-names>A</given-names></name><etal/></person-group><article-title>Association of sleep duration in middle and old age with incidence of dementia</article-title><source>Nat Commun</source><year>2021</year><volume>12</volume><pub-id pub-id-type="pmcid">PMC8058039</pub-id><pub-id pub-id-type="pmid">33879784</pub-id><pub-id pub-id-type="doi">10.1038/s41467-021-22354-2</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watts</surname><given-names>R</given-names></name><name><surname>Steinklein</surname><given-names>JM</given-names></name><name><surname>Waldman</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Filippi</surname><given-names>CG</given-names></name></person-group><article-title>Measuring glymphatic flow in man using quantitative contrast-enhanced MRI</article-title><source>Am J Neuroradiol</source><year>2019</year><volume>40</volume><fpage>648</fpage><lpage>651</lpage><pub-id pub-id-type="pmcid">PMC7048502</pub-id><pub-id pub-id-type="pmid">30679221</pub-id><pub-id pub-id-type="doi">10.3174/ajnr.A5931</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bradbury</surname><given-names>M</given-names></name><name><surname>Cserr</surname><given-names>H</given-names></name><name><surname>Westrop</surname><given-names>R</given-names></name></person-group><article-title>Drainage of cerebral interstitial fluid into deep cervical lymph of the rabbit</article-title><source>Am J Physiol Physiol</source><year>1981</year><volume>240</volume><fpage>F329</fpage><lpage>F336</lpage><pub-id pub-id-type="pmid">7223890</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cserr</surname><given-names>H</given-names></name><name><surname>Cooper</surname><given-names>D</given-names></name><name><surname>Suri</surname><given-names>P</given-names></name><name><surname>Patlak</surname><given-names>C</given-names></name></person-group><article-title>Efflux of radiolabeled polyethylene glycols and albumin from rat brain</article-title><source>Am J Physiol Physiol</source><year>1981</year><volume>240</volume><fpage>F319</fpage><lpage>F328</lpage><pub-id pub-id-type="pmid">7223889</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szentistványi</surname><given-names>I</given-names></name><name><surname>Patlak</surname><given-names>CS</given-names></name><name><surname>Ellis</surname><given-names>RA</given-names></name><name><surname>Cserr</surname><given-names>HF</given-names></name></person-group><article-title>Drainage of interstitial fluid from different regions of rat brain</article-title><source>Am J Physiol Physiol</source><year>1984</year><volume>246</volume><fpage>F835</fpage><lpage>F844</lpage><pub-id pub-id-type="pmid">6742132</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassett</surname><given-names>DS</given-names></name><name><surname>Bullmore</surname><given-names>ED</given-names></name></person-group><article-title>Small-world brain networks</article-title><source>The Neurosci</source><year>2006</year><volume>12</volume><fpage>512</fpage><lpage>523</lpage><pub-id pub-id-type="pmid">17079517</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bassett</surname><given-names>DS</given-names></name><name><surname>Bullmore</surname><given-names>ET</given-names></name></person-group><article-title>Small-world brain networks revisited</article-title><source>The Neurosci</source><year>2017</year><volume>23</volume><fpage>499</fpage><lpage>516</lpage><pub-id pub-id-type="pmcid">PMC5603984</pub-id><pub-id pub-id-type="pmid">27655008</pub-id><pub-id pub-id-type="doi">10.1177/1073858416667720</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fornari</surname><given-names>S</given-names></name><name><surname>Schäfer</surname><given-names>A</given-names></name><name><surname>Jucker</surname><given-names>M</given-names></name><name><surname>Goriely</surname><given-names>A</given-names></name><name><surname>Kuhl</surname><given-names>E</given-names></name></person-group><article-title>Prion-like spreading of Alzheimer’s disease within the brain’s connectome</article-title><source>J Royal Soc Interface</source><year>2019</year><volume>16</volume><elocation-id>20190356</elocation-id><pub-id pub-id-type="pmcid">PMC6833337</pub-id><pub-id pub-id-type="pmid">31615329</pub-id><pub-id pub-id-type="doi">10.1098/rsif.2019.0356</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putra</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>TB</given-names></name><name><surname>Chaggar</surname><given-names>P</given-names></name><name><surname>Goriely</surname><given-names>A</given-names></name></person-group><article-title>Braiding Braak and Braak: Staging patterns and model selection in network neurodegeneration</article-title><source>Netw Neurosci</source><year>2021</year><volume>5</volume><fpage>929</fpage><lpage>956</lpage><pub-id pub-id-type="pmcid">PMC8746141</pub-id><pub-id pub-id-type="pmid">35024537</pub-id><pub-id pub-id-type="doi">10.1162/netn_a_00208</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dale</surname><given-names>AM</given-names></name><name><surname>Fischl</surname><given-names>B</given-names></name><name><surname>Sereno</surname><given-names>MI</given-names></name></person-group><article-title>Cortical surface-based analysis: I. Segmentation and surface reconstruction</article-title><source>Neuroimage</source><year>1999</year><volume>9</volume><fpage>179</fpage><lpage>194</lpage><pub-id pub-id-type="pmid">9931268</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fischl</surname><given-names>B</given-names></name></person-group><article-title>Freesurfer</article-title><source>Neuroimage</source><year>2012</year><volume>62</volume><fpage>774</fpage><lpage>781</lpage><pub-id pub-id-type="pmcid">PMC3685476</pub-id><pub-id pub-id-type="pmid">22248573</pub-id><pub-id pub-id-type="doi">10.1016/j.neuroimage.2012.01.021</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>TB</given-names></name><name><surname>Chaggar</surname><given-names>P</given-names></name><name><surname>Kuhl</surname><given-names>E</given-names></name><name><surname>Goriely</surname><given-names>A</given-names></name></person-group><article-title>Protein-protein interactions in neurodegenerative diseases: a conspiracy theory</article-title><source>PLOS Comput Biol</source><year>2020</year><volume>16</volume><elocation-id>e1008267</elocation-id><pub-id pub-id-type="pmcid">PMC7584458</pub-id><pub-id pub-id-type="pmid">33048932</pub-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008267</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Putra</surname><given-names>P</given-names></name><name><surname>Thompson</surname><given-names>T</given-names></name><name><surname>Chaggar</surname><given-names>P</given-names></name><name><surname>Goriely</surname><given-names>A</given-names></name></person-group><article-title>Braiding Braak and Braak: Staging patterns and model selection in network neurodegeneration</article-title><source>Netw Neurosci</source><year>2021</year><fpage>1</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1162/netn_a_00208</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bennett</surname><given-names>RE</given-names></name><etal/></person-group><article-title>Tau induces blood vessel abnormalities and angiogenesis-related gene expression in P301L transgenic mice and human Alzheimer’s disease</article-title><source>Proc Natl Acad Sci</source><year>2018</year><volume>115</volume><fpage>E1289</fpage><lpage>E1298</lpage><pub-id pub-id-type="pmcid">PMC5819390</pub-id><pub-id pub-id-type="pmid">29358399</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1710329115</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrillo-Mora</surname><given-names>P</given-names></name><name><surname>Luna</surname><given-names>R</given-names></name><name><surname>Colín-Barenque</surname><given-names>L</given-names></name></person-group><article-title>Amyloid beta: multiple mechanisms of toxicity and only some protective effects?</article-title><source>Oxidative Medicine Cel l Longev</source><year>2014</year><volume>2014</volume><elocation-id>795375</elocation-id><pub-id pub-id-type="pmcid">PMC3941171</pub-id><pub-id pub-id-type="pmid">24683437</pub-id><pub-id pub-id-type="doi">10.1155/2014/795375</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Canobbio</surname><given-names>I</given-names></name><name><surname>Abubaker</surname><given-names>AA</given-names></name><name><surname>Visconte</surname><given-names>C</given-names></name><name><surname>Torti</surname><given-names>M</given-names></name><name><surname>Pula</surname><given-names>G</given-names></name></person-group><article-title>Role of amyloid peptides in vascular dysfunction and platelet dysregulation in Alzheimer’s disease</article-title><source>Front Cell Neurosci</source><year>2015</year><volume>9</volume><fpage>65</fpage><pub-id pub-id-type="pmcid">PMC4347625</pub-id><pub-id pub-id-type="pmid">25784858</pub-id><pub-id pub-id-type="doi">10.3389/fncel.2015.00065</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" position="float"><label>Figure 1</label><caption><p>A) Illustration of clearance rate estimation from regional signal intensities in the clearance phase; B) Brain connectome network with nodes representing parcellation regions and edges/connections constructed using data from the Human Connectome Project<sup><xref ref-type="bibr" rid="R30">30</xref></sup>; C) FYeeSnrfer atlas of the corresponding palliation recons; D) Estimated clearance rates and the corresponding clearance map for each subject in the reference cohort; E) Subject-averaged clearance map for the reference cohort; F) Illustration of Braak regions; G) Clearance rates averaged over Braak regions for each Braak region (Welch’s <italic>t</italic>-test: * for <italic>p</italic> &lt; 0.05, ** for <italic>p</italic> &lt; 0.01, and *** for <italic>p</italic> &lt; 0.001); H) Illustration of cortical lobes; I) Clearance rates averaged over cortical lobes for each cortical lobe (Welch’s <italic>t</italic>-test).</p></caption><graphic xlink:href="EMS206302-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>A, B) Simulated proteinopathy progression over the brain connectome network model for two sample subjects: relative misfolded protein concentration <italic>p</italic> and clearance levels λ at six time points 3, 8, 13, 18, 23, and 28 years; C) Brain-wide average misfolded protein concentration <inline-formula><mml:math id="M15"><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> over time for each subject, with the brain-wide average toxic protein concentration across subjects shown by the gray curve; D) Brain-wide average clearance rate <inline-formula><mml:math id="M16"><mml:mover accent="true"><mml:mi>λ</mml:mi><mml:mo>¯</mml:mo></mml:mover></mml:math></inline-formula> over time for each subject, with the brain-wide average clearance rate across subjects shown by the gray curve; E) Initial clearance rate in each network region λ<sub>0,<italic>i</italic></sub> for each subject, plotted against the time-to-threshold in that specific region <italic>i</italic>; F) Initial brain-wide average clearance rate <inline-formula><mml:math id="M17"><mml:msub><mml:mover accent="true"><mml:mi>λ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula> versus early-time toxic load for each subject; G) Percentage of network regions with subcritical initial clearance level versus early-time toxic load for each subject. The legend in C applies to C–G.</p></caption><graphic xlink:href="EMS206302-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>A) The simulated progression of proteinopathy across all subjects in the reference cohort in terms of the average misfolded protein concentrations (sagittal and lateral views of the right hemisphere) at years 0.5, 1, 1.5, 2.5, 5 and 10; B–C) Average simulated misfolded protein concentration in each of the lobes (B) and Braak regions (C), with activation maps below the biomarker curves. The activation maps show the order in which the regions reach a misfolded protein concentration of 10% (indicated by the dashed line on the biomarker curves above); D) The distribution of activation times for the Braak regions across subjects: for each of the Braak regions I–VI, each data point represents the average activation time of that Braak region, calculated as the mean across all ROIs within said region, for each subject (Welch’s <italic>t</italic>-test: * for <italic>p</italic> &lt; 0.05, ** for <italic>p</italic> &lt; 0.01).</p></caption><graphic xlink:href="EMS206302-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p>A) The misfolded protein concentration – averaged over the brain connectome – over time for all reference subjects (curve shows mean value across subjects with shading indicating the standard deviation) compared to with homogeneous initial clearance; B) The simulated progression of proteinopathy in terms of the misfolded protein concentrations (sagittal and lateral views of the right hemisphere) with homogeneous initial clearance at 1, 20, 25, 30, 35 and 40 years. (Note the difference in time scale compared to <xref ref-type="fig" rid="F3">Figure 3</xref>); Average simulated misfolded protein concentration in each of the lobes (C) and Braak regions (D), with activation maps below the biomarker curves. The activation maps show the order in which the regions reach a misfolded protein concentration of 10% (indicated by the dashed line on the biomarker curves above).</p></caption><graphic xlink:href="EMS206302-f004"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Regions of interest (ROIs) sorted by emulated level of involvement in simulated disease propagation (Z-scores) for the subject-specific heterogeneous initial clearance scenarios (reference cohort) and the homogeneous initial clearance scenario. The labels (l) and (r) denote the left and right hemispheres.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-right: solid thin;">Order</th><th align="left" valign="middle" colspan="2" style="border-right: solid thin;">Heterogeneous initial clearance</th><th align="left" valign="middle" colspan="2">Homogeneous initial clearance</th></tr><tr><th align="center" valign="middle" style="border-right: solid thin;"/><th align="left" valign="middle">ROI</th><th align="left" valign="middle" style="border-right: solid thin;">% inv.</th><th align="left" valign="middle">ROI</th><th align="left" valign="middle">% inv.</th></tr></thead><tbody><tr><td align="center" valign="middle" style="border-right: solid thin;">1</td><td align="left" valign="middle">Entorhinal (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.909</td><td align="left" valign="middle">Entorhinal (l)</td><td align="center" valign="middle">0.95</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">2</td><td align="left" valign="middle">Entorhinal (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.818</td><td align="left" valign="middle">Entorhinal (r)</td><td align="center" valign="middle">0.95</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">3</td><td align="left" valign="middle">Lateral Occipital (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.741</td><td align="left" valign="middle">Amygdala (l)</td><td align="center" valign="middle">0.864</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">4</td><td align="left" valign="middle">Inferior Temporal (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.714</td><td align="left" valign="middle">Hippocampus (l)</td><td align="center" valign="middle">0.836</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">5</td><td align="left" valign="middle">Superior Parietal (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.686</td><td align="left" valign="middle">Hippocampus (r)</td><td align="center" valign="middle">0.809</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">6</td><td align="left" valign="middle">Inferior Parietal (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.668</td><td align="left" valign="middle">Amygdala (r)</td><td align="center" valign="middle">0.750</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">7</td><td align="left" valign="middle">Caudal Middle Frontal (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.668</td><td align="left" valign="middle">Thalamus Proper (l)</td><td align="center" valign="middle">0.718</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">8</td><td align="left" valign="middle">Bankssts (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.609</td><td align="left" valign="middle">Putamen (l)</td><td align="center" valign="middle">0.718</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">9</td><td align="left" valign="middle">Caudal Middle Frontal (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.591</td><td align="left" valign="middle">Temporal Pole (l)</td><td align="center" valign="middle">0.695</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">10</td><td align="left" valign="middle">Middle Temporal (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.564</td><td align="left" valign="middle">Parahippocampal (l)</td><td align="center" valign="middle">0.691</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">11</td><td align="left" valign="middle">Superior Parietal (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.545</td><td align="left" valign="middle">Parahippocampal (r)</td><td align="center" valign="middle">0.691</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">12</td><td align="left" valign="middle">Precentral (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.532</td><td align="left" valign="middle">Thalamus Proper (r)</td><td align="center" valign="middle">0.691</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">13</td><td align="left" valign="middle">Inferior Temporal (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.532</td><td align="left" valign="middle">Pallidum (l)</td><td align="center" valign="middle">0.686</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">14</td><td align="left" valign="middle">Precentral (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.464</td><td align="left" valign="middle">Pallidum (r)</td><td align="center" valign="middle">0.686</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">15</td><td align="left" valign="middle">Inferior Parietal (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.459</td><td align="left" valign="middle">Accumbens Area (r)</td><td align="center" valign="middle">0.686</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">16</td><td align="left" valign="middle">Lateral Occipital (r)</td><td align="center" valign="middle" style="border-right: solid thin;">0.432</td><td align="left" valign="middle">Accumbens Area (l)</td><td align="center" valign="middle">0.682</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">17</td><td align="left" valign="middle">Precuneus (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.423</td><td align="left" valign="middle">Caudate (l)</td><td align="center" valign="middle">0.673</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">18</td><td align="left" valign="middle">Bankssts (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.418</td><td align="left" valign="middle">Caudate (r)</td><td align="center" valign="middle">0.664</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">19</td><td align="left" valign="middle">Middle Temporal (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.409</td><td align="left" valign="middle">Putamen (r)</td><td align="center" valign="middle">0.645</td></tr><tr><td align="center" valign="middle" style="border-right: solid thin;">20</td><td align="left" valign="middle">Pericalcarine (l)</td><td align="center" valign="middle" style="border-right: solid thin;">0.405</td><td align="left" valign="middle">Brain Stem</td><td align="center" valign="middle">0.627</td></tr></tbody></table></table-wrap></floats-group></article>